Open AccessResults from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
Author(s) -
Enrique Grande,
Teresa AlonsoGordoa,
Òscar Reig,
Emilio Esteban,
Daniel Castellano,
Xavier García del Muro,
María José Méndez,
Jesús García-Donás,
M. González Rodríguez,
J.A. Arranz-Arija,
Pilar López-Criado,
Javier MolinaCerrillo,
Begoña Mellado,
Carlos Álvarez-Fernández,
Guillermo de Velasco,
Miler Andrés Cuéllar-Rivas,
R.M. Rodríguez-Alonso,
Juan Francisco Rodríguez-Moreno,
Cristina Suárez-Rodríguez
Publication year - 2022
Publication title -
esmo open
Language(s) - English
Resource type - Journals
ISSN - 2059-7029
DOI - 10.1016/j.esmoop.2022.100463
Subject(s) - sunitinib , renal cell carcinoma , medicine , oncology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom